SPEED

Definition and Etymology of “Speed”

The term Speed functions primarily as a highly prevalent and enduring slang designation within illicit drug culture, referring generically to various psychostimulant substances, most centrally the drug amphetamine itself, or often methamphetamine. While the precise etymological origins are difficult to pinpoint definitively, the term likely arose in the mid-20th century, coinciding with the growing recreational use of these compounds. The nomenclature is a direct descriptive reference to the subjective effects experienced by the user—namely, the profound acceleration of physiological and cognitive processes, leading to increased wakefulness, energy, and perceived mental quickness. This terminology is crucial for understanding how these substances are perceived outside of clinical settings, emphasizing the rapid onset and forceful nature of the stimulant effects, contrasting sharply with the often sterile chemical names used in pharmaceutical contexts. The versatility of the term allows it to encompass not only pure amphetamine sulfate but also mixtures, sometimes adulterated, sold on the street market, making it an umbrella term for a broad class of powerful psychoactive agents.

In contemporary usage, the specific compound referred to by Speed can vary geographically and temporally, which poses inherent challenges for epidemiological study and harm reduction efforts. Historically, it might have referred strictly to prescription amphetamines diverted from legal channels, such as Benzedrine or Dexedrine. However, the production and proliferation of illicitly manufactured methamphetamine, particularly in crystallized forms, has led to this compound frequently being labeled as Speed, or sometimes “crystal speed.” This ambiguity highlights a significant distinction: while amphetamine and methamphetamine share structural similarities and mechanisms of action, methamphetamine is generally more potent, lipophilic, and has a longer half-life, resulting in more intense and prolonged effects on the central nervous system (CNS). Therefore, when utilizing the slang term, it is imperative to acknowledge the potential for referring to a substance with a significantly higher risk profile than standard amphetamine sulfate, underscoring the complexity inherent in non-clinical drug terminology.

For the purposes of this encyclopedia entry, the primary focus will be on the pharmacological and psychological profile of the amphetamine class of drugs, since Speed serves as its vernacular identifier. Amphetamines are synthetic compounds belonging to the phenethylamine class, characterized by their potent ability to stimulate the CNS. They achieve this effect primarily through modulating the release and reuptake of key monoamine neurotransmitters, including dopamine, norepinephrine, and serotonin. Understanding the mechanisms by which these drugs operate is essential for comprehending the vast spectrum of effects, ranging from acute euphoria and enhanced performance to severe psychiatric disturbances and cardiovascular complications. The societal preoccupation with Speed, whether utilized for performance enhancement, weight loss, or purely recreational purposes, reflects a deep-seated human desire to temporarily overcome fatigue and experience heightened states of alertness, often at considerable long-term physiological cost.

Chemical and Pharmacological Profile of Amphetamines

Amphetamine, chemically designated as alpha-methylphenethylamine, exists as two primary enantiomers, or mirror-image isomers: levo-amphetamine and dextro-amphetamine. The pharmaceutical preparations often utilize the pure dextro-isomer (dextroamphetamine) because it exhibits significantly greater potency in stimulating the CNS, primarily impacting dopaminergic pathways, compared to the levo-isomer, which has a comparatively greater affinity for peripheral and noradrenergic systems. The racemic mixture, containing equal parts of both isomers, is also prescribed and is often the composition found in illicitly produced Speed, though purity can vary dramatically. These molecules are structurally related to the naturally occurring catecholamines, which facilitates their interaction with monoamine transporters and receptors, essentially hijacking the body’s natural signaling pathways for alertness and reward. Their simple structure allows for relatively easy, though hazardous, clandestine synthesis, contributing significantly to their widespread availability in the illicit market.

The core mechanism defining the amphetamine class is its status as an indirect-acting sympathomimetic agent. Unlike direct agonists that bind directly to receptor sites, amphetamines exert their effects by causing the rapid, non-vesicular release of neurotransmitters from presynaptic nerve terminals. They accomplish this by entering the nerve terminal via the dopamine transporter (DAT) and norepinephrine transporter (NET). Once inside the cell cytoplasm, they interfere with the vesicular monoamine transporter 2 (VMAT2), reversing its function. This reversal leads to a massive expulsion of dopamine and norepinephrine into the synaptic cleft, overwhelming the postsynaptic receptors and causing the intense physiological and psychological activation characteristic of Speed use. Furthermore, amphetamines inhibit the reuptake of these monoamines by reversing the flow direction of the transporters themselves, thereby prolonging the presence and activity of the neurotransmitters in the synapse, leading to prolonged stimulation and potentiation of signaling.

The pharmacological half-life of amphetamine can be highly variable, depending heavily on the pH of the user’s urine, an unusual characteristic among psychoactive drugs. Because amphetamines are weak bases, an acidic urine pH promotes rapid ionization and excretion, shortening the effective duration of the drug. Conversely, alkaline urine pH decreases ionization, promoting passive tubular reabsorption in the kidneys and significantly extending the half-life and duration of action, potentially leading to prolonged intoxication and increased strain on the cardiovascular system. This variability necessitates careful monitoring in clinical settings but is entirely unregulated and unpredictable in the recreational use of Speed. The metabolism of amphetamines primarily occurs in the liver via hydroxylation and deamination pathways, producing various inactive or less active metabolites, though a significant portion of the drug is excreted unchanged, contributing to its potential for detection in toxicology screenings.

Historical Context and Early Uses

Amphetamine was first synthesized in 1887 by the Romanian chemist Lazar Edeleanu, though its psychoactive properties were not fully recognized or exploited until the 1930s. The initial clinical application arose from attempts to find a synthetic substitute for ephedrine, a naturally occurring stimulant used to treat asthma and congestion. The introduction of Benzedrine (racemic amphetamine) in 1932 marked its entry into Western medicine, initially marketed as a bronchial dilator sold in inhalers. However, physicians quickly noted its powerful CNS stimulating effects, leading to its prescription for a wide array of conditions, including narcolepsy, depression, and, perhaps most controversially, as a diet aid due to its potent appetite-suppressing properties. This early phase was characterized by a broad, often indiscriminate, application, driven by the novelty of a drug that could effectively combat fatigue and lift mood.

The widespread utility of amphetamines became globally apparent during World War II, when various militaries utilized the drugs extensively to maintain alertness and endurance among troops, pilots, and sailors during prolonged combat operations. Compounds such as Pervitin (methamphetamine) were routinely administered by Axis forces, and Benzedrine was similarly used by Allied forces, including the British and American air forces. The drugs were seen as essential tools for overcoming sleep deprivation, enhancing vigilance, and maintaining morale under extreme duress. This institutionalized mass consumption fundamentally normalized the use of these powerful stimulants for performance enhancement, setting a precedent that would profoundly influence recreational use decades later. The military application underscored the drug’s capacity to temporarily transcend natural human limitations, a quality central to its later appeal as Speed.

Post-war, the massive quantities of surplus amphetamines contributed directly to the burgeoning recreational market, particularly in countries like Japan, where intravenous use of methamphetamine spiked dramatically in the late 1940s and 1950s, creating the first major global epidemic of amphetamine abuse. In the United States and Europe, the 1960s saw a sharp rise in the non-medical use of prescription stimulants, particularly among truck drivers seeking to stay awake on long routes, students studying for exams, and eventually, counter-culture movements seeking intense psychedelic or euphoric experiences. It was during this period that the slang term Speed solidified its place in the popular lexicon, often associated with intravenous injection and the associated high-risk behaviors, leading to public health crises and increasingly stringent regulatory controls in the subsequent decades.

Mechanisms of Action in the Central Nervous System (CNS)

The primary therapeutic and intoxicating effects of amphetamines are mediated through the dramatic alteration of monoamine neurotransmission within key brain structures, particularly the striatum, prefrontal cortex, and the nucleus accumbens. The critical element is the massive surge of dopamine in the mesolimbic pathway, often referred to as the brain’s reward circuit. This intense dopaminergic activity is directly responsible for the profound feelings of euphoria, increased motivation, and heightened sense of well-being that users of Speed seek. By flooding the synapse with dopamine, the drug essentially hijacks the natural reward mechanisms, leading to powerful reinforcement of drug-seeking behavior and rapid development of psychological dependence. The magnitude of this release far exceeds what is achieved by natural rewards, explaining the intense “high” and the subsequent severe crash upon cessation.

In addition to dopamine, amphetamines exert significant influence on the norepinephrine system, primarily affecting structures related to vigilance, attention, and the fight-or-flight response. The increased release of norepinephrine (noradrenaline) in the CNS and periphery is responsible for the classic physiological signs of Speed intoxication: elevated heart rate, increased blood pressure, pupil dilation (mydriasis), and enhanced physical alertness. This noradrenergic surge enhances focus and reduces the perception of fatigue, which accounts for the drug’s utility in treating attention deficit hyperactivity disorder (ADHD) at controlled doses, but also contributes to the dangerous cardiovascular risks associated with recreational abuse. The simultaneous stimulation of both dopaminergic and noradrenergic pathways results in a synergistic effect that drives the intense, accelerated state for which the drug is named.

While the effects on dopamine and norepinephrine are dominant, amphetamines also interact with the serotonergic system, although generally to a lesser degree than substituted amphetamines like MDMA. This serotonergic activity, mainly through inhibition of the serotonin transporter (SERT) and promotion of serotonin release, contributes subtly to mood elevation and, at high doses, can contribute to altered sensory perception or anxiety. However, chronic or high-dose use of Speed, particularly methamphetamine, has been shown to be neurotoxic, specifically damaging dopaminergic and serotonergic nerve terminals in the brain. This neurotoxicity is thought to be mediated by oxidative stress and excessive neurotransmitter release, leading to long-term structural and functional changes in the brain that may underlie persistent cognitive deficits, depression, and difficulties in recovering normal reward function after abstinence.

Psychological and Behavioral Effects

The acute psychological effects following the ingestion of Speed are characterized by a state of hyper-arousal and increased self-confidence. Users typically report feelings of intense energy, reduced need for sleep, heightened concentration, and a notable elevation in mood, often progressing to intense euphoria. Cognitive tasks involving focus and short-term memory may initially seem enhanced, leading to the perception of improved performance, though this benefit is often offset by impaired judgment and an increased tendency toward repetitive or obsessive behavior (punding) when high doses are consumed. The drug dramatically increases motor activity and talkativeness, reflecting the overall acceleration of both mental and physical processes that defines the drug’s slang name.

As the dose increases or use becomes chronic, the psychological profile shifts dramatically towards negative outcomes. Anxiety, agitation, and paranoia become increasingly common, often manifesting as amphetamine-induced psychosis, which is clinically indistinguishable from paranoid schizophrenia. This psychotic state involves intense persecutory delusions, auditory or visual hallucinations, and disordered thought patterns. The user may believe they are being watched or hunted, leading to aggressive or defensive behaviors. This condition is a direct result of the excessive stimulation of the dopamine system in the limbic forebrain. Furthermore, the intense stimulation prevents normal sleep cycles, and prolonged wakefulness exacerbates the paranoia and psychotic symptoms, creating a vicious cycle of drug use and mental deterioration.

Behaviorally, the effects of Speed are often associated with impulsivity and risk-taking. The euphoric and confidence-boosting properties reduce inhibitions and impair the ability to assess consequences rationally. This can lead to dangerous choices, including engaging in unprotected sexual activity, driving recklessly, or increasing the frequency of drug use. A major behavioral consequence is the phenomenon known as “tweaking” or “running,” where the user remains awake for days, constantly seeking to maintain the high, leading to extreme exhaustion, nutritional deficits, and severe emotional lability. The crash that follows prolonged use is often marked by profound depression, lethargy (anergia), and intense dysphoria, driving the user to seek the drug again to alleviate the withdrawal discomfort, thereby facilitating the transition to compulsive use and addiction.

Risks, Tolerance, and Dependence

The risks associated with Speed use are substantial and involve both acute medical emergencies and chronic health deterioration. Acutely, the primary danger stems from the cardiovascular system strain induced by the noradrenergic effects. These risks include hypertensive crises, stroke (due to ruptured blood vessels from extreme blood pressure), cardiac arrhythmias, and myocardial infarction (heart attack). Hyperthermia, or dangerously elevated body temperature, is also a serious risk, particularly when the drug is used in hot environments or during strenuous physical activity, which can lead to rhabdomyolysis and subsequent kidney failure. Overdose, often involving highly pure or unknown quantities of illicitly manufactured Speed, is a medical emergency requiring rapid intervention to manage blood pressure and temperature.

Tolerance to the euphoric and appetite-suppressing effects of amphetamines develops rapidly and significantly. Users quickly find that the initial dose no longer produces the desired intensity of euphoria, prompting them to increase the dose or frequency of use to chase the initial high. This escalating tolerance is a key driver of compulsive use and dramatically increases the risk of overdose and toxicity. However, tolerance to some peripheral effects, such as the increase in heart rate and blood pressure, may develop more slowly or incompletely, meaning that chronic high-dose users are continuously subjecting their cardiovascular systems to dangerous stress, even if they no longer feel the initial pleasurable effects as intensely.

Dependence on Speed is characterized primarily by a profound psychological component, although physical withdrawal symptoms are also notable. Psychological dependence involves the intense craving for the drug, driven by the desire to avoid the dysphoric and exhausted state of withdrawal. Cessation of chronic use leads to a withdrawal syndrome often referred to as the “crash,” which typically includes severe depression, anhedonia (inability to experience pleasure), hypersomnia (excessive sleeping), and intense fatigue. The severity and duration of the depressive symptoms are often what precipitate relapse, as users attempt to self-medicate the withdrawal distress. Treatment for amphetamine dependence typically involves behavioral therapies, such as Cognitive Behavioral Therapy (CBT) and contingency management, as there are currently no FDA-approved pharmaceutical agents specifically for amphetamine withdrawal and recovery, emphasizing the complexity of overcoming this powerful addiction.

Clinical and Therapeutic Applications

Despite its reputation as Speed and its association with abuse, amphetamine and its derivatives remain valuable tools in modern clinical psychopharmacology, albeit under strict regulation. The primary current clinical uses include the management of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. In ADHD, amphetamines paradoxically help to calm and focus the patient, improving attention span and reducing impulsivity. This effect is thought to be mediated by the controlled increase in dopamine and norepinephrine in the prefrontal cortex, improving the executive function circuits that are deficient in individuals with ADHD. Formulations used clinically include dextroamphetamine sulfate (Dexedrine), mixed amphetamine salts (Adderall), and lisdexamfetamine (Vyvanse), a prodrug designed to reduce abuse potential by requiring metabolic activation for efficacy.

In the treatment of narcolepsy, a chronic neurological disorder characterized by overwhelming daytime sleepiness and sudden sleep attacks, amphetamines are highly effective. They function by promoting wakefulness through their strong CNS stimulant properties, allowing patients to maintain alertness and function normally throughout the day. The doses used clinically are typically low and highly controlled, designed to maximize therapeutic benefit while minimizing the risk of dependence and side effects. However, the potential for diversion of these prescription medications remains a significant public health concern, as they are frequently sought after for non-medical purposes, including academic enhancement or weight loss, contributing to the illicit supply of substances referred to as Speed.

Historically, amphetamines were used much more broadly, including for treatment-resistant depression and as adjuncts in weight loss programs. While their efficacy in suppressing appetite is undeniable, the risks of cardiovascular complications, tolerance, and dependence have generally led to their discontinuation for obesity treatment, often replaced by less potent or less addictive alternatives. Modern therapeutic guidelines emphasize careful patient selection, rigorous monitoring, and dose titration when prescribing amphetamines, acknowledging the high abuse liability inherent in these compounds. The differentiation between responsible clinical use and recreational abuse is crucial: therapeutic use aims for stable, sub-euphoric levels to normalize brain function, whereas recreational use seeks rapid, high-intensity stimulation resulting in the characteristic “speed” effects.

Societal Impact and Regulatory Status

The societal impact of Speed abuse has been profound, affecting public health, criminal justice systems, and economic productivity across the globe. Epidemics of use, particularly involving illicit methamphetamine, have strained healthcare resources due to the need for treating acute intoxication, psychosis, infectious diseases associated with injection (e.g., HIV, Hepatitis C), and long-term mental health consequences. The high potential for addiction leads to chronic unemployment, instability, and increased criminal activity related to drug acquisition and distribution. The destructive nature of high-dose, chronic amphetamine use impacts families and communities, necessitating extensive resources for rehabilitation and social support.

Globally, amphetamines are subject to strict international control under the United Nations Conventions on Psychotropic Substances, classifying them as Schedule II substances in the United States and similarly controlled categories worldwide. This regulatory framework acknowledges their legitimate medical utility but emphasizes the high potential for abuse. The control measures mandate strict limits on manufacturing, distribution, and prescription practices to prevent diversion into the illicit market. Enforcement efforts focus intensely on dismantling clandestine laboratories that produce illicit Speed, particularly high-purity methamphetamine, which represents a significant challenge due to the relative simplicity of the chemical precursors and synthesis methods.

The ongoing challenge for public policy lies in balancing the need for legitimate access to therapeutic amphetamines for conditions like ADHD and narcolepsy against the imperative to curb recreational abuse. Educational initiatives and harm reduction strategies are critical components of the response to Speed abuse. Harm reduction often involves providing information on safer routes of administration, recognizing overdose symptoms, and encouraging treatment seeking. Public awareness campaigns aim to counter the myth that amphetamines are harmless performance enhancers, emphasizing the severe risks of dependence, neurotoxicity, and acute medical complications, thereby addressing the persistent allure of the drug encapsulated by the term Speed.